Capstone Investment Advisors LLC Invests $537,000 in Enliven Therapeutics, Inc. $ELVN

Capstone Investment Advisors LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 10,577 shares of the company’s stock, valued at approximately $537,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Enliven Therapeutics during the second quarter worth about $221,255,000. Vestal Point Capital LP raised its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Siren L.L.C. bought a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $29,252,000. Jupiter Topco LLC acquired a new position in shares of Enliven Therapeutics in the 2nd quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $23,007,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Price Performance

ELVN stock opened at $57.86 on Friday. The company has a 50 day moving average price of $54.62 and a 200 day moving average price of $43.10. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The stock has a market capitalization of $4.24 billion, a PE ratio of -34.65 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ELVN shares. HC Wainwright raised their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Stifel Nicolaus increased their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Finally, Barclays initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the transaction, the chief financial officer owned 40,036 shares in the company, valued at $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of Enliven Therapeutics stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 196,849 shares of company stock worth $11,344,257 over the last 90 days. Insiders own 3.00% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.